Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)

Interim Results in ATTR Patients Show up to 93% Knockdown of TTR with Activity toward Both Wild-Type and Mutant TTR Multiple Doses of ALN-TTR02 Generally Safe and Well Tolerated with Once-Every-Four-Week and Once-Every-Three-Week Dosing Regimens CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase II trial of ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). The data were presented today at the 2013 Biennial Meeting of the Peripheral Nerve Society, held June 29 July 3 in St....